A PYMNTS Company

Singapore: Regulator rules against Fortis Healthcare’s RadLink sale

By  |  March 15, 2015

Fortis Healthcare Ltd on Friday announced that the Competition Commission of Singapore has ruled against its proposed divestment of 100% stake in its Singapore-based diagnostic and molecular imaging unit RadLink.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In its review of the proposed transaction, the commission cited the possible lessening of competition in the relevant market as the reason for its disapproval of the deal, Fortis said in a filing to stock exchanges. “Our step down subsidiary at Singapore, Fortis Healthcare Singapore Pte. Ltd has received a decision from the Competition Commission of Singapore wherein following a review of the proposed transaction, involving the acquisition of RadLink-Asia Pte Limited and its subsidiaries by Medi-Rad Associates Ltd, an indirect wholly owned subsidiary of IHH Healthcare Berhad, the regulator has indicated that if the proposed transaction is completed as contemplated, the combination may result in lessening of competition in the relevant market in Singapore,” the statement said.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

     

    Full Content: The Economic Times

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.